EUVIMEDEUVIMED entdecken
Crossref

Genomic Characterization of ETV6::RUNX1 ‐Positive Childhood B‐ALL in a Chinese Cohort: Novel Fusion Partners, Co‐Occurring Mutations, and Risk‐Stratifying Biomarkers

Hualei Luo iD, Guichi Zhou iD, Qian Li, Qiang Yao iD, Yunsheng Chen, Xue Tang iD, Shilin Liu, Huiying Ye, Huirong Mai iD, Xiaoying Fu iD, Ying Wang

Pediatric Blood & Cancer · 2026

DOI: 10.1002/1545-5017.70636 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2026. Verfasst von Hualei Luo und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory, Shenzhen Children's Hospital, Shenzhen, Guangdong, China. Hauptthemen laut MEDLINE: Core Binding Factor Alpha 2 Subunit, Oncogene Proteins, Fusion, Repressor Proteins, Mutation. Die Arbeit nennt 31 Literaturangaben. Gefördert von: Guangdong High-Level Hospital Construction Foundation, Shenzhen Fund for Guangdong Provincial High-Level Clinical Key Specialties, Shenzhen Key Medical Discipline Construction Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

ETV6::RUNX1 is the most common genetic abnormality in pediatric B‐cell acute lymphoblastic leukemia (ALL; ∼25%), yet the comprehensive genetic architecture and molecular predictors of intermediate‐risk (IR) stratification remain incompletely characterized.

Methods

We performed whole‐transcriptome sequencing (Illumina NovaSeq 6000, rRNA depletion, 41.70 Gb/sample) on bone marrow samples from 93 pediatric ETV6::RUNX1 ‐positive B‐ALL patients. Bioinformatics analysis included STAR alignment, MuTect2 variant calling, FusionCatcher fusion detection, and VEP annotation. The Jaccard index with permutation testing assessed mutation co‐occurrence; logistic regression identified independent predictors of IR classification.

Results

Beyond ETV6::RUNX1 , we identified 51 distinct fusion genes across the cohort, including the reciprocal RUNX1‐ETV6 (73.1%), chr8::KLF1210 (38.7%), and KLF12‐chr8 (34.4%). Somatic mutations in 249 genes were detected; the most frequent were KIAA1715 (17.2%), KRAS (11.8%), and NSD2 (10.8%). Network analysis revealed significant chromatin modifier co‐occurrence (KIAA1715‐KMT2C: J = 0.136, p = 0.015) and KRAS‐NRAS mutual exclusivity ( J = 0.000, p = 0.042). PTCH1 (OR = 3.50, 95% CI 0.21–58.49, p = 0.41) and GNB1 (OR = 6.5, 95% CI 1.2–34.8, p = 0.029) mutations independently predicted IR classification. chr8::KLF1210 fusion correlated with higher Day‐19 MRD levels ( p = 0.038).

Conclusions

GNB1 mutation represents a novel independent predictor of IR stratification in ETV6::RUNX1 ‐positive B‐ALL. The chromatin modifier co‐occurrence module and extensive fusion architecture reveal biological heterogeneity within this favorable‐risk subtype, with potential implications for risk‐adapted therapeutic strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Core Binding Factor Alpha 2 SubunitOncogene Proteins, FusionRepressor ProteinsMutationProto-Oncogene Proteins c-etsBiomarkers, TumorPrecursor B-Cell Lymphoblastic Leukemia-LymphomaHumansETS Translocation Variant 6 ProteinFemaleChildMaleChild, PreschoolInfantAdolescentPrognosisGenomicsEast Asian People

Stichwörter der Autor:innen

B‐ALLETV6::RUNX1fusion genespediatricrisk stratificationsecondary mutations

Substanzen

ETS Translocation Variant 6 ProteinCore Binding Factor Alpha 2 SubunitOncogene Proteins, FusionRepressor ProteinsProto-Oncogene Proteins c-etsBiomarkers, TumorRUNX1 protein, human

Autor:innen und Institutionen

  • Department of Laboratory, Shenzhen Children's Hospital, Shenzhen, Guangdong, China.
  • Department of Hematology, Shenzhen Children's Hospital, Shenzhen, Guangdong, China.

ORCID-Profile: Hualei Luo, Guichi Zhou, Qiang Yao, Xue Tang, Huirong Mai, Xiaoying Fu

Förderung

  • Guangdong High-Level Hospital Construction Foundation
  • Shenzhen Fund for Guangdong Provincial High-Level Clinical Key Specialties
  • Shenzhen Key Medical Discipline Construction Fund
  • Shenzhen Clinical Research Center for Child Health and Disease

Zitieren

APA

Luo, H., Zhou, G., Li, Q., Yao, Q., Chen, Y., Tang, X., Liu, S., Ye, H., Mai, H., Fu, X., & Wang, Y. (2026). Genomic Characterization of ETV6::RUNX1 ‐Positive Childhood B‐ALL in a Chinese Cohort: Novel Fusion Partners, Co‐Occurring Mutations, and Risk‐Stratifying Biomarkers. Pediatric Blood & Cancer. https://doi.org/10.1002/1545-5017.70636

Vancouver

Luo H, Zhou G, Li Q, Yao Q, Chen Y, Tang X, et al. Genomic Characterization of ETV6::RUNX1 ‐Positive Childhood B‐ALL in a Chinese Cohort: Novel Fusion Partners, Co‐Occurring Mutations, and Risk‐Stratifying Biomarkers. Pediatric Blood & Cancer. 2026. doi:10.1002/1545-5017.70636

BibTeX
@article{Luo2026,
  author = {Luo, Hualei and Zhou, Guichi and Li, Qian and Yao, Qiang and Chen, Yunsheng and Tang, Xue and Liu, Shilin and Ye, Huiying and Mai, Huirong and Fu, Xiaoying and Wang, Ying},
  title = {Genomic Characterization of ETV6::RUNX1 ‐Positive Childhood B‐ALL in a Chinese Cohort: Novel Fusion Partners, Co‐Occurring Mutations, and Risk‐Stratifying Biomarkers},
  journal = {Pediatric Blood & Cancer},
  year = {2026},
  doi = {10.1002/1545-5017.70636}
}
Kostenlos starten →